✦ LIBER ✦

PRS9 COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS OF RESISTANCE

✍ Scribed by S Cure; S Quilici; M Martin; T Evers; T Schaberg; H Mitfessel

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PRS7 COST-EFFECTIVENESS OF FENSPIRIDE IN

✍ M Pirozynski; W Bartminski; M Czech; T Faluta; R Pachocki 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PRS6 A CANADIAN COST ANALYSIS OF 4 RANDO

✍ E Tsakonas; J Stewart; J Chang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PID19: COST-EFFECTIVENESS OF ONCE-DAILY

✍ J Hutton; J Ryan; D Conway 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

PRS4 THE COST-EFFECTIVENESS OF DRUG THER

✍ M Martin; S Quilici; T Evers; M Kubin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PRS9 THE COST-EFFECTIVENESS OF TARGETED

✍ L Moore; M Martin; S Quilici; DE Low; R Grossman; A Kureishi; M Kubin; B Jaszews 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Using competence network collaboration a

✍ Uwe Siebert; Gaby Sroczynski; Jürgen Wasem; Wolfgang Greiner; Ulrike Ravens-Sieb 📂 Article 📅 2005 🏛 Springer 🌐 French ⚖ 261 KB